Bladder cancer-associated protein (BLCAP) is downregulated in bladder cancer and has been identified as a prognostic biomarker for human bladder cancer. We previously reported that BLCAP mRNA is decreased in cervical cancer tissues, and overexpression of BLCAP was found to inhibit cell growth and induce apoptosis in the human cervical cancer HeLa cell line To investigate the BLCAP protein expression in cervical cancer and its potential clinical indications, we developed a polyclonal antibody against human BLCAP to assess the BLCAP protein expression in 30 cervical cancer tissues and 30 non-tumor cervical tissues from patients. Western blotting data showed that a single band of recombinant protein was probed by antiserum of BLCAP and no band was probed by pre-immune serum. BLCAP expression was significantly downregulated in cervical carcinoma tissues compared with its expression in the non-tumor cervical tissues. Moreover, cervical carcinoma tissues from patients with stage III-IV had significantly lower BLCAP expression percentage compared with stage I-II. Similarly, a significantly lower BLCAP expression percentage was observed in moderately/poorly differentiated tumor tissues and in the tumor tissues from patients with lymphatic metastasis (LM) compared with well-differentiated tumor tissues and non-LM patients, respectively. Our results suggest that decreased BLCAP protein expression is associated with poor prognosis and it could be a potential bio-index to predict cervical tumor patient outcome.